Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

A legfontosabb adatok

Ki végzi
Arthrex, Inc.
Hol
Danville, Knoxville és Winston-Salem (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
45 fő vett részt
Kezdés
2024. máj. 13.
Befejezés
2026. febr. 9.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • ACP Max™
  • Depo-Medrol®
A regiszteradat frissítve
2026. február 18.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject voluntarily decides to participate and signs the consent form
  • Subject is ≥ 18 to 75 years of age
  • Subject presents with symptomatic knee OA despite at least 6 months of one of the following conservative treatments; oral medications, analgesics, and/or anti-inflammatory medications
  • Subject has documented radiographic evidence of OA in the tibiofemoral or patellofemoral compartment of the target knee (Kellgren-Lawrence Grades II-III), using radiographs performed within 12 weeks of screening
  • Subject has a WOMAC pain score (WOMAC A) of at least 8 out of 20 and at least moderate degree of difficulty (a score of 2) for at least 2 questions on performing daily activities
  • Subject consents to a washout period of NSAIDs and analgesics 7 days before each study visit (except low-dose aspirin for prevention of cardiovascular disease)
  • Subject has a Body Mass Index ≤ 35 kg/m2

Ki nem vehet részt

  • Subject has received an IA injection of corticosteroids in the target knee within 4 months prior to screening
  • Subject did not achieve initial pain relief from prior corticosteroid injections
  • Subject has received an IA injection of HA in the target knee within 6 months prior to screening
  • Subject has received an IA injection of PRP in the target knee at any time prior to screening
  • Subject had prior open surgery on the target knee within 12 months or knee arthroscopy within 6 months
  • Subject plans to participate in other clinical trials involving medical or surgical intervention in the next 12 months
  • Subject with plans to undergo any elective orthopedic surgery in the next 12 months
  • Subject requires pain management therapy not related to the target knee (with the exception of acetaminophen)
  • Subject has clinically 3+ effusion of the target knee (stroke test grading system)
  • Subject has a history of coagulopathy
  • Subject has an inflammatory disease of either knee other than OA
  • Subject which, in the investigator's opinion, has an underlying medical condition(s) that could interfere with the evaluation of the outcome
  • Subject with any condition (including cognitive impairment) that, in the investigator's opinion, might interfere with the evaluation of the study objectives
  • Subject has an infection at the affected joint
  • Subject has a history of major trauma to the target knee within one year
  • Subject has a known hypersensitivity to Depo-Medrol and its constituents
  • Subject has Grade I or IV in the target knee according to the Kellgren-Lawrence grading scale
  • Subject has significant (> 10°) valgus or varus deformities as evidenced by standard of care x-ray
  • Subject has joint pain reflected by a VAS score of > 35 mm out of 100 mm scale in the contralateral knee at the time of screening
  • Subject with a positive pregnancy test or breastfeeding
  • Subject has rheumatoid arthritis or gout

Helyszínek itt: Egyesült Államok

  • Spectrum Medical, Inc.Danville, Egyesült Államok
  • AMR KnoxvilleKnoxville, Egyesült Államok
  • The Center for Clinical ResearchWinston-Salem, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).

A vizsgálat 2 csoportja

  • ACP Max™A vizsgált kezelés

    Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™

  • 40 mg of methylprednisolone acetateMár használt kezelés, összehasonlításként

    Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.

    Kezelés: Depo-Medrol®

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. február 18.